Announcements

Announcement on behalf of AP Biosciences that application for Phase I human clinical trial of Bispecific Antibody, AP203, has been granted by TFDA

1.Date of occurrence of the event:2022/11/14 2.New drug name or code:Bispecific Antibody, AP203 3.Indication:Bispecific antibody AP203 is a second-generation cancer immunotherapy developed by AP Biosciences (hereinafter referred to as APBio). …

Announcement on behalf of APBio’s resolution to lift non-competition restrictions for directors at 2022 extraordinary Shareholders’ Meeting

1.Date of the shareholders’ meeting resolution:2022/11/09 2.Name and title of the managerial officer with permission to engage in competitive conduct: Director Frank Chen Director Jeng Her Director Ming-Tain Lai Director …

Announcement on behalf of AP Biosciences. regarding its by-election of director and supervisor at 2022 first extraordinary General Shareholders’ Meeting

1.Date of occurrence of the change:2022/11/09 2.Elected or changed position (Please enter institutional director, institutional supervisor, independent director, natural-person director or natural-person supervisor):natural-person director and natural-person supervisor 3.Title and name …

Announcement on behalf of AP Biosciences’ important resolutions of 2022 first extraordinary General Shareholders’ Meeting

1.Date of the special shareholders’ meeting:2022/11/09 2.Important resolutions: (1)Matters for Discussion: A.Amendments to the Company’s “Rules for Scope of Duties and Execution of Power of Supervisors” B.Amendments to the Company’s …

Announcement of the Consolidated Financial Statements for the third quarter of 2022 were approved by the Board of Directors

1.Date of the board of directors submitted or approved:2022/11/04 2.Date of the audit committee approved:2022/11/04 3.Start and end dates of financial reports or unaudited financial information of the reporting period …

The Chairman decided the record date of 2022 first issuance of RSU according to the resolution Of BOD

1.Date of occurrence of the event: 2022/10/25 2.Company name: OBI Pharma Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”): Head office 4.Reciprocal shareholding ratios: Not applicable 5.Cause …

Announcement on behalf of AP Biosciences that the BOD resolved to convene 2022 first extraordinary General Shareholders’ Meeting

1.Date of the board of directors resolution:2022/10/18 2.Extraordinary shareholders’ meeting date:2022/11/09 3.Extraordinary shareholders’ meeting location: Building A. 2F., No. 19-10, Sanchong Rd., Nangang Dist., Taipei City (Conference room located on …

OBI-822 “Cancer Immunotherapy by Immune Activation or Immune Modulation via Globo Series Antigens“ was granted by USPTO

1.Date of occurrence of the event:2022/10/13 2.Company name:OBI Pharma Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office 4.Reciprocal shareholding ratios:Not applicable 5.Cause of occurrence:OBI Pharma Inc. …

Announcement on behalf of AP Biosciences of the resignation of its institutional director

1.Date of occurrence of the change: 2022/10/6 2.Elected or changed position (Please enter institutional director, institutional supervisor, independent director, natural-person director or natural-person supervisor): institutional director 3.Title and name of …

OBI PHARMA INC. to attend investor conference hosted by MASTERLINK SECURITIES

1.Date of institutional investor conference:2022/10/12 2.Time of institutional investor conference:14:30:00 NST 3.Location of institutional investor conference:Taipei New Horizon (Address: 6F., No. 88, Yanchang Rd., Xinyi Dist., Taipei City 110, Taiwan) …